We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Tianlong Highlights Molecular Diagnostics and Blood Screening Solutions at ADLM 2026

By LabMedica International staff writers
Posted on 28 Jul 2026

Tianlong Science and Technology is participating in the ADLM 2026 Clinical Lab Expo, taking place July 28–30 in Anaheim, California. More...

At booth 1047, the company is presenting molecular diagnostic and blood-screening solutions, including the Panall X1600, Genesys Sp96, Aurora PANA X6, Panall 8000, and blood-screening reagents.

The Panall X1600 is a fully automated molecular diagnostic system that processes up to 16 samples and detects as many as 48 targets in a single run. Its two independently controlled modules allow laboratories to perform different assays simultaneously, while automation covers the workflow from sample processing through result generation.

Tianlong is also showcasing the Genesys Sp96 Real-Time PCR System, which can be expanded from 96 to 384 wells through a replaceable module without requiring recalibration. The platform supports high-resolution melting analysis for applications such as mutation and single-nucleotide polymorphism detection.

For high-throughput blood screening, the Aurora PANA X6 automates original-tube loading, barcode scanning, capping and decapping, sample pooling, nucleic acid extraction, and PCR setup. The system processes up to 576 samples per run and incorporates directional airflow, ultraviolet disinfection, HEPA filtration, negative pressure, and other contamination-control features.

The Panall 8000 provides an integrated option for laboratories with lower sample volumes. It combines sample loading, nucleic acid extraction, PCR preparation, amplification, detection, and result analysis and can process up to eight samples simultaneously.

Tianlong is additionally presenting a real-time PCR blood-screening kit for the qualitative detection of hepatitis B virus DNA, hepatitis C virus RNA, HIV-1 RNA, and HIV-2 RNA in serum or plasma. The kit supports both individual testing and six-sample pooling and is available in prefilled and non-prefilled formats.

Through its ADLM 2026 exhibit, Tianlong is highlighting technologies designed to reduce manual handling, consolidate molecular workflows, and support testing volumes ranging from small batches to high-throughput blood screening.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Hematology Consumables
Bioblood Devices
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.